Replimune Shares Top 52-Week High After Submitting Application for Melanoma Treatment
Replimune Group Shares Are Trading Higher After the Company Announced It Received Breakthrough Therapy Designation Status for RP1 and Will Submit an RP1 Biologics License Application to the FDA Under an Accelerated Approval Pathway.
Express News | Replimune Receives Breakthrough Therapy Designation for Rp1 and Submits Rp1 Biologics License Application to the FDA Under the Accelerated Approval Pathway
J.P. Morgan Maintains Replimune(REPL.US) With Buy Rating, Cuts Target Price to $16
Insider Sale: Chief Medical Officer of $REPL (REPL) Sells 7,246 Shares
BMO Capital Maintains Replimune(REPL.US) With Buy Rating, Maintains Target Price $14
